Dec. 31 at 1:51 PM
$ALT While @Cryptobearcat (and others) are trying to convince you of the safety/tolerability of
$ALT vs.
$AKRO based on drug-related discontinuations, I think it goes without saying that he's looking at the wrong metric to look at the adverse effects of each drug.
A truer comparison is the AEs (or TEAEs). This gives you a true, unmotivated metric that shows the safety and tolerability effect of the drug. While
$ALT has "conveniently" not produced their 48W Secondary Endpoint data for TEAEs, we can look to 24W in which
$ALT had the following safety/tolerability:
1.2mg AEs - 78% of subjects
1.8mg AEs - 81% of subjects
This is drastically different than the ~0% drug-related discontinuation rates that
$ALT wants you to focus on.
This is
$ALT's tactic. They fluff you with data you want to hear and then slide in the real, damning, important data later. Many on this board don't realize that, but WS and BP noticed.
Follow/Subscribe for more perspective.
Cheers!
Ref. Lancet
